SOLICITATION NOTICE
66 -- Human Methylation 450 DNA Analysis Bead Chip kits for NHLBI’s Framingham Heart Study
- Notice Date
- 8/22/2014
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-HI-2014-237-CDB
- Archive Date
- 9/13/2014
- Point of Contact
- Chris Bocus, Phone: 3014027888
- E-Mail Address
-
chris.bocus@nih.gov
(chris.bocus@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION: THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), Office of Acquisitions (OA), on intends to negotiate and award a purchase order on a sole source noncompetitive basis to Illumina Inc., 5200 Illumina Way, San Diego, CA, 92122-4616 to provide one (1) Human Methylation 450 DNA Analysis BeadChip Kit. PROCUREMENT: The contractor shall provide the following: 1. One (1) Human Methylation 450 DNA Analysis BeadChip Kit. o Each Human Methylation 450 DNA Analysis Bead Chip can process twelve samples and analyze >450,000 loci. o Each package contains eight (8) BeadChips, along with reagents for amplifying, fragmenting, hybridizing, labeling and detecting ninety-six (96) DNA samples. BACKGROUND: The mission of the NHLBI Division of Intramural Research (DIR) is to perform robust scientific and clinical research leading to a better understanding of biology and clinical pathology. To attain this goal, we have built a strong basic science foundation and coupled it closely with innovative technology development and outstanding clinical research both at the NIH Clinical Center and in partnership with local hospitals. The purview of our research is broad, encompassing investigations into the basic principles of molecular, cellular, and organ-level biology and their relationship to disease. Some current areas of fundamental interest include single molecule structure; protein assembly; molecular and cell biology; cell signaling and motility; membrane trafficking; physiology; systems biology; engineering and technology development. Insights into disease mechanisms derived from basic studies form the basis for translational research into new diagnostic and therapeutic approaches. DIR investigators also conduct concept-based clinical studies in the areas of interventional and surgical cardiology; pulmonary medicine; sickle cell anemia; bone marrow transplant; and hematologic disorders. The Center for Population Studies located in Framingham Massachusetts and associated with the Framingham Heart Study focuses on Epidemiology of cardiovascular disease. Providing state-of-the-art training in basic, translational, and clinical research for the next generation of scientific and clinical leaders is a high priority. This program provides opportunities for scientists and trainees to work together towards a better understanding of molecular machines, the cell, the body, and ultimately the treatment of human diseases. Epigenetics refers to genomic modifications that do not involve alterations in DNA sequence, but are responsible for functional derangements. Epigenetics has emerged as one of the most promising areas of science that will help address sizeable gaps in our understanding of the inheritance of common traits and environmental influences on disease. Epigenetic mechanisms enable cells to respond quickly to environmental changes. Consequently, they provide a link between genes and the environment. It has been proposed that inter-individual variation in the epigenetics modification of genes may explain a larger part of the phenotypic variation observed in humans than differences in genotype alone. DNA methylation was the first epigenetic element to be identified and is the best characterized. It plays a critical role in the maintenance of cell functions, and alterations in DNA methylation are believed to be pivotal in promoting a variety of diseases. Most of the current knowledge of epigenetics has been generated in animals. It is crucial now to obtain this information in humans, and DNA methylation is an obvious place to start. Existing knowledge of DNA methylation in humans, especially related to CVD risk, is in its very preliminary stages. The availability of new, high throughput technology and the extensive resources of the Framingham Heart Study and the SABRe CVD Initiative provide a timely, invaluable platform upon which the research can be conducted. PURPOSE AND OBJECTIVE: This acquisition is for the purpose of procurement of Illumina Human 450K DNA Methylation bead chips for use by the Framingham Heart Study. ANTICIPATED PERIOD OF PERFORMANCE: To be negotiated upon award. JUSTIFICATION: The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted as prescribed in FAR Part 10-Market Research. Illumina is the sole provider and manufacturer of this BeadChip. This is the only DNA Methylation array product on the market with unique capability of having more than 200,000 methylation sites. There are no re-sellers or compatible products. REGULATORY AUTHORITY: This acquisition is conducted under the authority of 41 U.S.C. 253(c) as set forth in FAR Part 13.106-1 (b) (1), Soliciting from a single source not exceeding the simplified acquisition threshold, and is exempt from the requirements of FAR Part 6, Competition Requirements. ADDITIONAL INFORMATION: Industry Classification (NAICS) Code is 334516, Analytical Laboratory Instrument Manufacturing and the Small Business Size Standard is 500 Employees. This acquisition is conducted under the procedures as prescribed in FAR subpart 12-Acquisition of Commercial Items and FAR subpart 13-Simplified Acquisition Procedures. The solicitation document, the incorporated provisions and clauses are those in the Federal Acquisition Circular 2005-76, effective July 25, 2014. The determination by the Government to award a purchase order on a sole source noncompetitive basis to provide one (1) Human Methylation 450 DNA Analysis BeadChip Kit to Illumina Inc., 5200 Illumina Way, San Diego, CA, 92122-4616., is based upon the market research conducted in accordance with one or more of the techniques specified in FAR Part 10-Market Research, Subpart 10.002(b)(2). This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by August 29, 2014 at 1:00 p.m. EST. Responses must reference synopsis number HHS-NIH-NHLBI-CSB-HI-2014-237-CDB, may be submitted to the National, Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6121A, Bethesda, Maryland 20892-7902, Attention: Chris Bocus. Response may be submitted electronically to chris.bocus@ nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-HI-2014-237-CDB/listing.html)
- Place of Performance
- Address: Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN03477401-W 20140824/140822235626-d0ca744a2fb500c89ed88876fab04e51 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |